Literature DB >> 23905143

The Beta Lactam Antibiotics as an Empirical Therapy in a Developing Country: An Update on Their Current Status and Recommendations to Counter the Resistance against Them.

Bhaskar Thakuria1, Kingshuk Lahon.   

Abstract

In a developing country like India, where the patients have to bear the cost of their healthcare, the microbiological culture and the sensitivity testing of each and every infection is not feasible. Moreover, there are lacunae in the data storage, management and the sharing of knowledge with respect to the microorganisms which are prevalent in the local geographical area and with respect to the antibiotics which are effective against them. Thus, an empirical therapy for treating infections is imperative in such a setting. The beta lactam antibiotics have been widely used for the empirical treatment of infections since the the discovery of penicillin. Many generations of beta lactams have been launched with, the claims of a higher sensitivity and less resistance, but their sensitivity has drastically decreased over time. Thus, the preference for beta lactams, especially the cephalosporins, as an empirical therapy, among the prescribers was justified initially, but the current sensitivity patterns do not support their empirical use in hospital and community acquired infections. There is a need for increasing the awareness and the attitudinal change among the prescribers, screening of the antibiotic prescriptions, the strict implementation of antibiotic policies in hospital settings, restricting the hospital supplies and avoiding the prescriptions of beta lactams, a regular census of the local sensitivity patterns to formulate and update the antibiotic policies, upgradation of the laboratory facilities for a better and faster detection of the isolates, proper collection, analyses and sharing of the data and the encouragement of the research and development of newer antibiotics with novel mechanisms of action.

Entities:  

Keywords:  AmpC; Beta lactams; ESBL; Empirical use; HLAR; MBL; MRSA; Resistance

Year:  2013        PMID: 23905143      PMCID: PMC3708238          DOI: 10.7860/JCDR/2013/5239.3052

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  72 in total

Review 1.  Phage therapy: a reappraisal of bacteriophages as antibiotics.

Authors:  Jameel M Inal
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2003       Impact factor: 4.291

Review 2.  Carbapenemases.

Authors:  D M Livermore
Journal:  J Antimicrob Chemother       Date:  1992-06       Impact factor: 5.790

3.  New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe.

Authors:  M J Struelens; D L Monnet; A P Magiorakos; F Santos O'Connor; J Giesecke
Journal:  Euro Surveill       Date:  2010-11-18

4.  Observation on integron carriage among clinical isolates of Klebsiella pneumoniae producing extended-spectrum beta-lactamases.

Authors:  A Bhattacharjee; M R Sen; P Prakash; A Gaur; S Anupurba; G Nath
Journal:  Indian J Med Microbiol       Date:  2010 Jul-Sep       Impact factor: 0.985

5.  Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute.

Authors:  M S Kumar; V Lakshmi; R Rajagopalan
Journal:  Indian J Med Microbiol       Date:  2006-07       Impact factor: 0.985

6.  Zinc-dependent carbapenemases in clinical isolates of family Enterobacteriaceae.

Authors:  S Rai; V Manchanda; N P Singh; I R Kaur
Journal:  Indian J Med Microbiol       Date:  2011 Jul-Sep       Impact factor: 0.985

Review 7.  ESBL - from petri dish to the patient.

Authors:  S Bhattacharya
Journal:  Indian J Med Microbiol       Date:  2006-01       Impact factor: 0.985

8.  Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center.

Authors:  P E Coudron; E S Moland; K S Thomson
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

Review 9.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

10.  Occurrence and detection of AmpC beta lactamases among clinical isolates of E. coli and K. pneumoniae causing UTI.

Authors:  Ekadashi Rajni; U Rawat; V L Malhotra; G Mehta
Journal:  J Commun Dis       Date:  2008-03
View more
  24 in total

1.  Robust, linear correlations between growth rates and β-lactam-mediated lysis rates.

Authors:  Anna J Lee; Shangying Wang; Hannah R Meredith; Bihan Zhuang; Zhuojun Dai; Lingchong You
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-02       Impact factor: 11.205

Review 2.  The oxadiazole antibacterials.

Authors:  Jeshina Janardhanan; Mayland Chang; Shahriar Mobashery
Journal:  Curr Opin Microbiol       Date:  2016-05-27       Impact factor: 7.934

Review 3.  Biosynthetic process and strain improvement approaches for industrial penicillin production.

Authors:  Amol M Sawant; Koteswara Rao Vamkudoth
Journal:  Biotechnol Lett       Date:  2022-01-09       Impact factor: 2.461

4.  In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Mojgan Sabet; Ziad Tarazi; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 5.  Relationship of environmental disturbances and the infectious potential of fungi.

Authors:  Hazael Hernandez; Luis R Martinez
Journal:  Microbiology       Date:  2018-02-05       Impact factor: 2.777

Review 6.  An Updated Review on the Synthesis and Antibacterial Activity of Molecular Hybrids and Conjugates Bearing Imidazole Moiety.

Authors:  Renzo Rossi; Maurizio Ciofalo
Journal:  Molecules       Date:  2020-11-04       Impact factor: 4.411

7.  Wet-dry cycles protect surface-colonizing bacteria from major antibiotic classes.

Authors:  Yana Beizman-Magen; Maor Grinberg; Tomer Orevi; Nadav Kashtan
Journal:  ISME J       Date:  2021-07-12       Impact factor: 10.302

Review 8.  Measures used to assess the burden of ESBL-producing Escherichia coli infections in humans: a scoping review.

Authors:  Kathryn L McDonald; Sarah Garland; Carolee A Carson; Kimberly Gibbens; E Jane Parmley; Rita Finley; Melissa C MacKinnon
Journal:  JAC Antimicrob Resist       Date:  2021-02-14

9.  uCARE Chem Suite and uCAREChemSuiteCLI: Tools for bacterial resistome prediction.

Authors:  Saurav Bhaskar Saha; Vijai Kumar Gupta; Pramod Wasudeo Ramteke
Journal:  Genes Dis       Date:  2020-06-30

Review 10.  Zebrafish as a Screening Model to Study the Single and Joint Effects of Antibiotics.

Authors:  Roxana Jijie; Gabriela Mihalache; Ioana-Miruna Balmus; Stefan-Adrian Strungaru; Emanuel Stefan Baltag; Alin Ciobica; Mircea Nicoara; Caterina Faggio
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.